149sek
-0,7 %
Date:2024-04-19Time:17:29:55Latest report:Q4-2023List:First NorthTicker:KAN
Market Cap:180 msekEnterprise Value:134 msekNet Sales:- msekEarnings:-64,9 msekEmployees:0ISIN:SE0015658570

Ratios

10-year key figure history for Kancera turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Kancera with index and moving average MA50 and MA200.

Stockprice:1,49
MA50:2,28
MA200:3,89
Price/MA200:-61,8 %
RSI (14):37,9
Price/MA50:-34,7 %

Description

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Biotechnology